THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, December 08, 2021
The pharma outsourcing sector is being driven by the increasing pressure on pharmaceutical corporations to improve their return on investments.
Fremont, CA: Over the last few years, the healthcare market has seen significant transformations. Some of the themes that influenced the pharma industry were the growing importance of contract research organizations (CROs) and contract manufacturing organizations (CMOs), the rapid adoption of innovative technologies such as automation and artificial intelligence, and the increasing pressure from governments around the world to reduce the healthcare burden. Pharmaceutical businesses have used outsourcing to improve operating efficiencies, extend geographical presence, and expand therapeutic capabilities and on-demand services.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The pharma industry is shifting towards outsourcing because of:
Bundled deals
By delivering end-to-end solutions, service bundling is projected to improve outsourcing efficiency. Pharma businesses will benefit from this not only in terms of cost savings, but also in terms of increased control, visibility, and flexibility. In the R&D arena, the industry anticipated bundled solutions in trial design, conduct, and reporting.
Motivation for outsourcing has shifted
Outsourcing allows businesses to save money on labor, infrastructure, and other overhead costs. Although cost reduction remains the primary goal for outsourcing numerous services across the sector, there has been a significant shift in outsourcing motivations in certain large pharmaceutical companies. In today's market, pharma companies cite enhanced quality and shorter time-to-market as the primary reasons for outsourcing their business tasks to CROs (contract research and development organizations) (CDMOs).
Strategic Partner Selection
Pharma businesses today desire long-term agreements with a small number of vendors, which is a significant departure from previous models, in which major pharma companies could have anywhere from 10 to 300 CROs and CMOs as partners. Pharma companies are trying to reduce their CRO and CMO partnerships to 2-3 CRO and less than 50 CMO contacts in the current market. In the value chain, strategic partnerships and collaborations lower costs and boost efficiency.
Increased Service Range
To cut costs, pharmaceutical corporations are increasingly outsourcing their services. Formulation development, analytical and testing services, API production, clinical trial management, and solid dose manufacturing are just a few services that are gaining traction among pharma companies.
See Also: Business Management Review
More in News